The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s BMY Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of ...
The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.The approval, for individuals aged 12 ...
A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
BriGene Biosciences supported Grit with technology transfer, manufacturing, and regulatory requirements for the IND for GT307.
The FDA declined to endorse leucovorin as a treatment for autism, but approved the drug to treat cerebral folate deficiency, a rare neurological disorder. The Trump administration has touted ...
Results from a global phase 3 clinical trial led by investigators at Mass General Brigham show that the medication ...
The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results